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Objectives. The aim of this study was to describe heart trans- 
plantation in children with congenital heart disease and to 
compare the results with those in children undergoing transplan- 
tation for other cardiac diseases. 
Background. Reports describe decreased survival after heart 
transplantation in children with congenital heart disease com- 
pared with those with cardiomyopathy. However, transplantation 
is increasingly being considered in the surgical management of 
children with complex congenital heart disease. Present-day re- 
sults from this group require reassessment. 
Methods. The diagnoses, previous operations and indications 
for transplantation were characterized in children with congenital 
heart disease. Pretransplant course, graft ischemia time, post- 
transplant survival and outcome (rejection frequency, infection 
rate, length of hospital stay) were compared with those in children 
undergoing transplantation for other reasons (n = 47). 
Results. Thirty-seven children (mean [-+SD] age 9 + 6 years) 
with congenital heart disease underwent transplantation; 86% 
had undergone one or more previous operations. Repair of 
extracardiac defects at transplantation was necessary in 23 pa- 
tients. Causes of death after transplantation were donor failure in 
two patients, surgical bleeding in two, pulmonary hemorrhage in 
one, infection in four, rejection in three and graft atherosclerosis 
in one. No difference in 1- and 5-year survival rates (70% vs. 77% 
and 64% vs. 65%, respectively), rejection frequency or length of 
hospital stay was seen between children with and without congen- 
ital heart disease. Cardiopulmonary bypass and donor ischemia 
time were significantly longer in patients with congenital heart 
disease. Serious infections were more common in children with 
than without congenital heart disease (13 of 37 vs. 6 of 47, 
respectively, p = 0.01). 
Conclusions. Despite the more complex cardiac surgery re. 
quired at implantation and longer donor ischemic time, heart 
transplantation can be performed in children with complex con- 
genital heart disease with success imilar to that in patients with 
other cardiac diseases. 
(J Am Coil Cardiol 1995;26:743-9) 
Surgical advances have greatly increased the survival of chil- 
dren with congenital heart disease. However, myocardial fail- 
ure can occur early or late after operation for complex 
congenital heart disease. Late cardiac mortality has been 
reported after surgical repair of tetralogy of Fallot (5%), aortic 
stenosis (17%) and the Mustard procedure for transposition f
the great arteries (15%) (1). Fontan et al. (2) reported an 
increase in risk of death from 6 to 15 years after the Fontan 
operation. 
As survival after heart ransplantation has improved, this 
option is more often considered inthe surgical management of 
children with complex congenital heart disease. According to 
the registry of the International Society for Heart Transplan- 
tation (3), congenital heart disease has become the primary 
indication for transplantation in the pediatric population, with 
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the proportion of children with congenital heart disease un- 
dergoing transplantation increasing from 16% in 1984 to 46% 
in 1993. Beyond the neonatal age range, most children with 
congenital heart disease undergoing transplantation have un- 
dergone one or more attempts at palliative or corrective 
cardiac surgery. Heart transplantation in these children pre- 
sents a number of special problems. The indications and 
optimal timing of transplantation can be ditficult to determine 
in patients with complex heart disease, and the type of 
reconstructive surgery of extracardiac defects required at 
transplantation must be carefully considered. Previous tudies 
have reported many unique technical approaches to heart 
transplantation in patients with systemic and pulmonary ve- 
nous anomalies (4-6), pulmonary artery stenoses (7), hypo- 
plastic left heart syndrome (8), dextrocardia (9) and transpo- 
sition of the great arteries (10-12). 
It has been reported (13,14) that mortality among children 
with congenital heart disease is higher than that for children 
undergoing transplantation forother easons, but recent stud- 
ies (15,16) have shown improved survival. The present study 
describes the pretransplantation a d posttransplantation 
courses of a relatively arge series of children with and without 
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Table 1. Diagnosis and Surgical History.' for 37 Study Patients 
Pt Age Surv 
No. Diagnosis (yr) (mo) Status Previous Operation 
1 Hypoplastic Icft heart syndrome 0.0 0.5 Dead None 
2 Ebstein's anomaly 0.1 0.3 Dead None 
3 Single right ventricle, common atrium, d-malposition of the great artcrics, pulmonary, 7.3 49.4 Alive None 
stenosis, asplenia syndrome 
4 VSD, cardiomyopathy 12.7 55.6 Alive None 
5 Ventricular inversion,/-transposition of the great arteries, tricuspid insufficiency, 18.1 61.8 Alive None 
complete heart block 
6 Pulmonary' atresia, intact ventricular septum, coronau arte U fistulae (I.5 31.4 Alive Ao-PA shunt 
7 Single right ventricle, complete AV canal defect, mitral atresia, d-transposition of the I. I 26.0 Alive Ao-PA shunt 
great arteries, pulmonary,, stcnosis, anomalous ystemic venous return, polysplenia 
syndrome 
8 Double-outlet right ventricle, complete AV canal defect, hypoplastic mitral valve. 1.2 0.9 Dead Ao-PA shunt 
pulmonau stenosis, aortic stenosis 
9 AV canal defect (complete), pulmonary stenosis 2.1 4.7 Dead Ao-PA shunt 
10 Double-outlet right ventricle, d-malposition of the great arteries, VSD. hypoplastic 8.0 39.4 Alive Ao-PA shunt 
mitral valve, pulmonary, atresia 
Tricuspid atresia, small VSD, pulmonary atresia, mitral insufficiency 17.7 90.8 Alive 
d-Transposition of the great arteries, VSD, mitral atresia, pulmonaw stcnosis 4.6 123.5 Alive 
AV canal defect (partial), subaortic stenosis 12.8 25.6 Alive 
d-Transposition of the great arteries, VSD, coarctation of the An 13.4 40.7 Alive 
11 
12 
13 
14 
15 Hypertrophic ardiomyopathy, coarctation of the Ao 15.8 77.8 Alive 
16 Shone's complex, coarctation ot the Ao, aortic stenosis, subaortic stenosis 12.3 35.2 Alive 
17 3.7 46.1 Alive 
18 Tetralogy of Fallot 13.8 92.4 Dead 
19 Tetralogy of Fallot, pulmonary, atrcsia 12.7 0.0 Dead 
20 Tetralogy of Fallot, tricuspid insufficiency 3.7 17.0 Alive 
21 Ventricular inversion,/-transposition of the great arteries, VSD, pulmonary atresia, 3.7 54.2 Alive 
severe tricuspid insufficiency 
22 Ventricular inversion,/-transposition of the great arteries, VSD. pulmemary stenosis. 13.8 39.9 Dead 
dextrocardia, tricuspid insufficiency 
23 Ventricular inversion,/-transposition of the great arteries, VSD, pulmonary' stenosis, 16.8 0,0 Dead 
severe tricuspid insufficiency 
24 Ventricular inversion,/-transposition of the great arteries, VSD, subaortic 18.3 26.0 Alive 
obstruction 
25 Multiple VSDs 4.5 1.6 Dead 
26 Double-inlet LV, vcntricular inversion,/-malposition f the great arteries 15.9 60.3 Alive 
27 Double-inlet LV, ventricular inversion, t-malposition of the great artcrics, restrictive 15.1 0.9 Dead 
bulboventricular foramen 
28 Double-inlet LV. ventricular inversion./-malposition f the great arteries, pulmona U 1131 50.2 Alive 
stenosis 
29 Double-inlet LV. vcntricular inversion, normally related great arteries, 2.3 26.2 Alive 
bulboventricular foramen stenosis 
30 Double-inlet LV. ventricular inversion, normally related great arteries, pulmonary, 15.3 29.1 Alive 
stenosis 
31 Double-outlet hypoplastic right ventricle, tricuspid stenosis, pulmonary stcnosis, 17.0 19.3 Alive 
VSD, l-malposition of the great arteries 
32 Single LV, straddling tricuspid valve, hypoplastic right ventricle. 15.(I 0.0 Dead 
d-malposition of the great artcrics 
33 Single LV, vcntricular inversion, l-malposition of the great arteries, left AV valve 3.8 0.0 Dead 
atresia, bulhoventricular stenosis 
34 
Shone's complex, coarctation of the Ao, aortic sten{~sis, subaortic stcnosis 
35 
36 
37 
Ao-PA shunt 
PA band; atrial septectomy 
Repair; Konno procedure 
Coarctation repair; Mustard 
procedure and VSD closure 
Coarctation repair; myectomy 
Coarctation repair; aortic 
valvotomy; aortic valve 
replacement; Konno procedure 
Coarctation repair; aortic 
valvotomy; Konno procedure 
Repair 
Repair; conduit replacement 
Repair; tricuspid valve annuloplasty 
Ao-PA shunt; repair 
Repair; tricuspid valve replacement 
Repair; tricuspid valve replacement 
PA band; VSD closure 
Repair 
PA band; Fontan 
PA Band; Fontan; Fontan revision; 
LV-Ao conduit placement 
Ao-PA shunts; Fontan 
Ao-PA shunt; bidirectional Glenn 
procedure 
Ao-PA shunt; Glenn shunt; Fontan 
Fontan 
Ao-PA shunts; Fontan; Fontan 
revision; Fontan takedown 
PA band, atrial septectomy; 
bulboventricular foramen 
enlargement; Fontan 
Ao-PA shunt; Fontan Tricuspid atresia, VSD, hypoplastic right ventricle, pulmonary stenosis, normally 111.3 20.1 Alive 
related great arteries 
Tricuspid atresia, VSD, pulmonary' stcnosis, normally related great arteries 18.2 14.6 Alive Ao-PA shunt; Glenn shunt; Fontan 
Hypoplastic left heart syndrome 1.2 9.9 Dead Norwood 1 
Hypoplastic left heart syndrome 0.9 24.7 Alive Norwood 1 
Ao aorta; AV atrioventricular: PA ~ pulmonary, arteu: Pt patient; LV left ventricle; Surv = survival; VSD = ventricular septal defect. 
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Table 2. Indications for Transplantation in 37 Children With 
Congenital Heart Disease 
Indication No. of Pts 
Reparative operation ot feasible 
Ventricular failure (no previous cardiac surgery) 
Ventricular failure (after cardiac surgery) 
Surgical repair 
Palliative operation 
Norwood 1 procedure 
Low cardiac output after Fontan operation 
2 
3 
23 
13 
8 
2 
9 
Pts = patients. 
congenital heart disease undergoing transplantation a d com- 
pares their outcome. 
Methods  
Patients. Eighty-four consecutive children undergoing pri- 
mary heart transplantation from June 1984 to August 1993 
were included in the present study (44 boys, 40 girls; mean 
[_+SD] age at time of transplantation 9.3 _+ 6.2 years, range 1 
week to 18.5 years; mean follow-up time from transplantation 
37 _+ 31 months, range of 0.1 to 122). The follow-up period 
ended in July 1994. Two patients underwent heterotopic heart 
transplantation because of severely elevated pulmonary vascu- 
lar resistance, and 82 underwent orthotopic transplantation. 
Indication for heart transplantation. Congenital heart dis- 
ease with intractable congestive heart failure or complex 
congenital heart disease with severe deterioration not amena- 
ble to surgical correction were the indications for transplanta- 
tion in 37 patients (44%). Thirty-four patients were older than 
6 months of age at the time of operation. The number of 
children per year with the diagnosis of congenital heart disease 
undergoing transplantation at our institution increased from 2 
patients in 1984 to 10 in 1992. For the 47 patients without 
congenital heart disease, the indication for transplantation was 
congestive heart failure refractory to maximal medical therapy. 
The underlying diagnoses of these patients were dilated car- 
diomyopathy (27 patients), endocardiofibroelastosis (7 pa- 
tients), hypertrophic cardiomyopathy (7 patients) and adria- 
mycin-induced cardiomyopathy (5 patients). One additional 
patient underwent transplantation because of congestive heart 
failure and ventricular arrhythmias secondary to an unresect- 
able left ventricular tumor. 
Study groups. The patients were classified into two groups 
for comparison; those with congenital heart disease and those 
with other cardiac diseases. The following preoperative vari- 
ables were compared between the two groups: gender, age at 
transplantation, duration of congestive heart failure before 
transplantation, number of inotropic medications required and 
pulmonary vascular esistance index before transplantation. 
The posttransplantation variables of donor heart ischemia 
time, cardiopulmonary b pass time, patient survival, duration 
of posttransplantation hospital stay, rejections per patient- 
month and serious bacterial or fungal infections requiring 
3% 5% 4 AO/ 
[ ]  None (n=5) 
16c [ ]  One (n=lO) 
• Two (n=13) 
[ ]  Three (n=6) 
27% 
[ ]  Four (n=l) 
[ ]  Five (n=2) 
Figure 1. Number of cardiac surgery procedures per patient per- 
formed before transplantation n 37 patients. 
intravenous antibiotic agents in the early postoperative (<3 
months) period were also compared between the two groups. 
The incidence of graft atherosclerosis and lymphoproliferative 
disorders was also compared. 
Immunosuppression protocol. Before 1986, all children 
undergoing transplantation (n = 14) were maintained on 
cyclosporine (serum trough levels of 150 to 200 ng/dl) and 
prednisone (0.2 mg/kg body weight per day). Six of these 
children had congenital heart disease, and eight had cardio- 
rnyopathy. After November 1986, azathioprine was added to 
the protocol in doses of 1.5 to 2 mg/kg per day, and cyclospo- 
rine trough levels were maintained at 200 ng/dl (n = 70). 
Endomyocardial biopsies were performed on a routine basis, 
and histologic evidence of acute rejection was treated with 
increased corticosteroid doses. Refractory episodes of rejec- 
tion were treated with OKT3, rabbit ATG, methotrexate or
total lymphoid irradiation, as clinically indicated. 
Statistical analysis. Continuous variables were compared 
between patients with and without congenital heart disease by 
unpaired t test. Chi-square analysis was used to compare 
discrete variables. Survival between the two groups was com- 
pared using the Wilcoxon and log-rank tests for the association 
of response with covariates. The power of the study to detect a 
10% difference in survival was 30%. 
Results  
Patients with congenital heart disease. Diagnoses, urgical 
histories and indications for transplantation. The mean (_+SD) 
age of the 37 children with congenital heart disease who 
underwent transplantation was 9.3 _+ 6.4 years with a mean 
length of follow-up of 31.2 _+ 29 months. The diagnoses and 
surgical histories of these children are presented in Table 1. 
Five patients had not undergone cardiac surgery before 
transplantation. Reparative surgery was not feasible in two 
newborns; three patients developed severe ventricular dysfunc- 
tion in addition to their congenital heart defect (Table 2). 
Thirty-two patients (86%) developed significant ventricular 
failure after palliative or corrective surgery. Eight patients 
were in New York Heart Association functional class III at the 
time of transplantation; 29were in class IV. Twenty-six (70%) 
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Figure 2. Closed heart procedures performed before transplantation 
in 20 patients: aorta to pulmonary artery shunt (n = 13, solid area); 
coarctation of the aorta (n = 4, hatched area); pulmonary artery 
banding (n = 3, open area). 
52% 
4% 
A ~ S  
36% 
Figure 3. Open heart procedures performed before transplantation in 
26 patients: bidirectional Glenn procedure (n= 1, crosshatched area); 
Norwood 1 (n = 2, open area); Fontan procedure (n = 9, hatched 
area); complete r pair (n = 13; solid area). 
of the 37 patients were receiving a mean of 1.8 (range 1 to 5) 
inotropic agents at the time of transplantation; eight were 
mechanically ventilated. 
Twenty-two patients (60%) had undergone two or more 
cardiac procedures, and five previous operations had been 
performed in each of two patients (Fig. 1). Closed heart 
procedures were performed before transplantation in 20 pa- 
tients (54%); the most common procedure was an aortopul- 
monary shunt (Fig. 2). Heart transplantation was performed 
after a closed heart procedure alone in seven patients, in six 
after an aortopulmonary shunt and in one after pulmonary 
artery banding. The remaining 13 patients underwent one or 
more additional cardiac surgical procedures before transplan- 
tation. 
Twenty-five patients (68%) had undergone a mean of 1.6 _+ 
0.7 open heart surgeries before heart transplantation. The 
mean interval from the last open heart procedure to transplan- 
tation was 3.4 +_ 3.0 years. Thirteen patients had undergone 
one or more operations to correct their congenital heart 
defect; 12 patients with a single ventricle had undergone 
palliative open heart surgery (Fig. 3). 
Additional surgical procedures performed at the time of 
transplantation i cluded takedown of a Fontan or Glenn 
procedure, repair of pulmonary artery stenosis and rerouting 
of the systemic or pulmonary venous return (Table 3). In all 
patients who required reconstruction f the systemic venous 
return, endomyocardial biopsies could be performed, when 
necessary, through the rerouted superior or inferior vena cava. 
Mortality and cause of death. Thirteen of the 37 patients 
with congenital heart disease died after transplantation, 11 
(85%) within 9 months after the procedure. Causes of death 
included onor heart failure, right heart failure secondary to 
pulmonary hypertension, postoperative hemorrhage, pulmo- 
nary hemorrhage, infection, rejection and graft atherosclerosis 
(Table 4). Of the three late deaths, one resulted from pneu- 
monia after a prolonged hospital stay, and two occurred in 
adolescents who died at 40 and 92 months posttransplantation 
because of noncompliance with their immunosuppression pro- 
tocol. 
Residual extracardiac defects. Four patients had the pres- 
ence of aortopulmonary collateral channels documented by 
descending aorta angiography after transplantation. Three had 
undergone a Fontan procedure, and one had two previous 
Blalock-Taussig shunts placed for severe pulmonary stenosis 
in the context of a polysplenia syndrome. In three of the four 
patients, high output heart failure developed within 2 weeks of 
transplantation, necessitating increased inotropic support and 
coil embolization of the major collateral channels. 
Functional status. Twenty-two f the 25 patients currently 
alive are participating fully in age-appropriate activities. One 
11-year old patient is limited by severe scoliosis and restrictive 
lung disease and attends chool half-time. Two preschool 
children are mildly hypotonic and are undergoing physical 
therapy for delayed gross motor function. 
Comparison: Patients with and without congenital heart 
disease. Preoperative variables. The pretransplantation cli i- 
cal profiles of the patients with and without congenital heart 
disease indicated no significant difference between the groups 
with respect o age at transplant, gender, duration of conges- 
tive heart failure or number of inotropic medications required 
before transplantation (Table 5). The mean pulmonary vascu- 
lar resistance index was relatively high for both groups, but 
there was no significant difference between the two groups. 
Patient survival. There was no significant difference in 
patient survival between the two groups (Fig. 4). Three pa- 
tients with congenital heart disease have undergone retrans- 
plantation for ventricular failure secondary to chronic rejec- 
tion; however, overall graft survival was also not significantly 
different between the two groups. Regardless of diagnosis, 
overall survival after transplantation was significantly ower in 
all patients undergoing transplantation before mid-1986 com- 
pared with those undergoing transplantation si ce mid-1986. 
Only 2 (14%) of 14 children who underwent transplantation 
before mid-1986 still survive compared with 53 (75%) of 70 
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Table 3. Additional Surgical Procedures in23 Patients at Time 
of Transplantation 
Procedure No. of Pts 
Takedown of Fontan or Glenn procedure 
Repair of branch pulmonary artery stenosis 
lntraatrial baffle of left-sided SVC and/or 
IVC to right atrium 
Takedown Mustard procedure 
10 
10 
2 
IVC (SVC) = inferior (superior) vena cava; Pts = patients. 
children who underwent transplantation since mid-1986. How- 
ever, survival was not significantly different between patients 
with congenital heart disease and those with other cardiac 
diseases undergoing transplantation before mid-1986 (none of 
six vs. two of eight survivors). Similarly, no difference in 
survival was seen by diagnosis among patients undergoing 
transplantation after mid-1986. Ten of the 12 deaths that 
occurred in the patients who underwent transplantation before 
mid-1986 were due to rejection, whereas 3 of 17 deaths after 
mid-1986 were secondary to rejection. Thus, the type of 
immunosuppression was significantly associated with the dif- 
ference in survival between the two time periods (17). 
lntraoperative and postoperative variables. Intraoperative 
and postoperative ariables were compared between the pa- 
tients with and without congenital heart disease (Table 6). 
Graft ischemia time and cardiopulmonary b pass time were 
significantly longer in patients with congenital heart disease. 
The number of patients with an early bacterial or fungal 
infection after transplantation was significantly higher in the 
group with than without congenital heart disease (13 of 37 vs. 
6 of 47, respectively). The infections een in the group with 
congenital heart disease included bacterial sepsis (eight pa- 
tients), bacterial and Candida albicans sepsis (two patients), 
Staphylococcus aureus and Aspergillus empyema (one patient), 
toxoplasmosis (one patient) and bacterial pneumonia (one 
patient). 
Coronary artery disease and lymphoproliferative disease. The 
incidence of graft atherosclerosis was no different between 
Table 4. Cause of Death in 13 Patients With Congenital 
Heart Disease 
Cause of Death No. of Pts 
Donor failure 
Right heart failure 
Postoperative hemorrhage 
Pulmonary hemorrhage 
Infection (<6 mo after transplantation) 
Aspiration pneumonia 
Fungal and CMV sepsis 
Acute rejection secondary to improper cyclosporine dosage 
Graft atherosclerosis 
Infection (9 mo after transplantation) 
Noncompliance with immunosuppressive protocol 
CMV ~ cytomegalovirus; Pts = patients, 
Table 5. Comparison of Preoperative Variables 
CHD No CHD 
(n = 37) (n = 47) p Value 
Age (yr) 9.4 _+ 6.5 9.5 -+ 6.1 NS 
Gender (M/F) 22/15 32/15 NS 
Duration of CHF 15.2 _+ 26.9 21.9 -+ 28.5 NS 
(months) 
Inotropic support before 1.2 +_ 1.l 1.0 -+ 1.0 NS 
transplantation 
(medications/pt) 
PVRI (U/m 2) 5.9 + 3.4 6.8 -+ 4.7 NS 
Data presented are mean value + SD or number of patients. CHD : 
congenital heart disease; CHF = congestive heart failure; pt = patient; PVRI = 
pulmonary vascular esistance index. 
children with and without congenital heart disease. Sixty of the 
84 patients had selective coronary artery angiography or 
postmortem histologic examination of the coronary arteries of 
the transplanted heart. Five of 23 patients with and 5 of 37 
patients without congenital heart disease had evidence of graft 
atherosclerosis. 
Lymphoproliferative disorders have been diagnosed in 5 of 
the 84 patients in the present study. Three patients had the 
pretransplantation diagnosis of congenital heart disease, and 
two patients underwent transplantation because of end-stage 
congestive heart failure secondary to cardiomyopathy. 
Discuss ion  
Transplantation for congenital heart disease. The present 
study describes the use of transplantation as a surgical ap- 
proach to children with congenital heart disease and end-stage 
heart failure. The majority of patients were outside the neo- 
natal period and had undergone previous palliative or correc- 
tive surgery. Most patients had the clinical findings of severe 
ventricular dysfunction and were critically ill in the intensive 
care unit at the time of transplantation. Thus, expected 1-year 
survival in this patient group without transplantation was 
extremely low, in contrast o the 1-year survival of 70% and 
5-year survival of 64% after transplantation. 
Early studies uggested that congenital heart disease was an 
independent risk factor for death after heart ransplantation in 
children outside the neonatal age range. Trento et al. (14) 
reported 4 survivors after transplantation i  10 patients with 
congenital heart disease; four of the six deaths were attributed 
to donor right heart failure. Right ventricular decompensation 
has also been reported as a cause of death in other series 
(18-20). Although the mean pulmonary vascular esistance 
index of the patients in the present study was 6.0 units, only 
one patient died of donor right heart failure. As previously 
reported from this institution (2l), aggressive pretransplanta- 
tion and posttransplantation measures to lower pulmonary 
vascular esistance and prevent donor right heart failure most 
likely contributed to the lower incidence of death from right 
heart failure. In a follow-up study by Armitage et al., 11 
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Figure 4. Patient survival after transplantation in pa- 
tients with and without congenital heart disease 
(CHD). 
additional patients with congenital heart disease were added 
to the original 10 patients, and the improved 1-year survival 
of 60% was attributed to "improved myocardial protection, 
surgical experience and more aggressive post-transplant 
care" (15). 
Reported 1-year survival after transplantation in children 
with congenital heart disease ranges from 3 of 11 patients 
reported by Baum et al. (19) to 9 of 10 patients reported by 
Chartrand (18). The 70% 1-year survival rate in the present 
series is similar to that of 53% to 71% reported by other 
investigators (9,13,16). The majority (83%) of deaths in the 
present series occurred early after transplantation, although 
only two deaths from postoperative hemorrhage could be 
directly attributed to the complexity of the structural heart 
disease. The 5-year survival of 64% in the present study is also 
comparable to long-term survival after transplantation re- 
ported in the other smaller series (13,15,16). 
Additional reconstructive surgery was performed at the 
time of transplantation in 62% of the patients in the present 
series. Many innovative techniques have been described (4-12) 
to reconstruct and repair extracardiac defects. However, to our 
knowledge comparison of donor ischemia time and cardiopul- 
Table 6. Comparison f Intraoperative and Postoperative Variables 
CHD No CHD p Value 
Donor heart ischemia 221 ± 70 180 - 64 0.004 
time (min) 
Cardiopulmonan, 220 ± 78 116 ± 37 0.0001 
bypass time (rain) 
Posttransplantation 37 * 51 28 + 22 NS 
hospital stay (days) 
Perioperative nfection 13 6 0.01 
Rejection/pt-mo 0.2 + 0.57 0.15 ± 0.23 NS 
Data presented are mean value = SD or number of patients. CHD = 
congenital heart disease; pt = patient. 
monary bypass time between patients with and without con- 
genital heart disease has not been reported previously. In the 
present study, both donor heart ischemia time and cardiopul- 
monary bypass time were longer in the patients with congenital 
heart disease, implying that the time required for reconstruc- 
tive surgery before transplantation contributed to the dura- 
tion of graft ischemia. Improved coordination of the timing 
of organ donor procurement to increase the operative time 
allotted to prepare the recipient with congenital heart 
disease for transplantation may help shorten donor ischemia 
time. 
Infections. The incidence of significant postoperative in- 
fections in our patients with congenital heart disease was 35%. 
The most common infection was bacterial sepsis, although 
three patients did have fungal sepsis. Ten of the 13 patients 
had undergone previous cardiac surgery, which may have led to 
slower wound healing because of decreased vascularity of scar 
tissue and a predisposition to infection; however, the etiology 
of the increased susceptibility o infection in these patients is 
not clear. 
Aortopulmonary collateral channels. The incidence of aor- 
topulmonary collateral channels in patients i reported (22) to 
be 36% in patients after the Fontan or bidirectional Glenn 
procedure. Aortopulmonary collateral channels have not been 
reported after transplantation for congenital heart disease. 
The incidence in the present series was similarly 33% (3 of 9) 
in the patients after a Fontan procedure; two patients devel- 
oped significant hemodynamic compromise and required cath- 
eter embolization of the collateral channels. 
Summary. Transplantation should be considered under 
various circumstances for the child with complex congenital 
heart disease. The decision to replace rather than to attempt 
palliation or repair in very high risk cases must be tailored to 
the individual patient, weighing the complexity of the repara- 
tive surgery and the possibility of success against he risks of 
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the transplant operation and consequences of long-term im- 
munosuppression in the pediatric patient. Some children have 
no other options because all other operative choices have been 
exhausted. At our institution, the only anatomic ontraindica- 
tion to heart transplantation is severe pulmonary artery hypo- 
plasia or pulmonary vein stenosis. The present study demon- 
strates that despite longer graft ischemia nd bypass times and 
a higher incidence of postoperative infections, survival after 
transplantation i children with congenital heart disease is 
comparable to survival after transplantation i  children with 
other cardiac diseases, predominantly cardiomyopathy. Trans- 
plantation was performed successfully in six of nine patients 
with a "failed" Fontan procedure, offering these severely 
debilitated patients the possibility of a return to normal 
activities. In addition, six of nine patients with single-ventricle 
anatomy in whom a Fontan procedure was contraindicated 
also survived transplantation. Our data demonstrate hat heart 
transplantation ffers the possibility of excellent medium-term 
survival for children with a variety of complex congenital heart 
lesions and should be considered as a therapeutic option in 
children with myocar-dial dysfunction or in those patients with 
no other viable options. 
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